Maze Therapeutics, Inc. Share Price & Technical Analysis
MAZE · $25.78 (+0.12%)
Healthcare / Biotechnology
$25.78
+0.12%
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral sm…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 2 years shown)
-3% return in May, 5% avg return in past 3 year May month.
-37% return in 2026, 132% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | 5% | -33% | -13% | -3% | – | – | – | – | – | – | – | -37% |
| 25 | -1% | -23% | -10% | -14% | 5% | 22% | 20% | 1% | 77% | 28% | 17% | 10% | 132% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.42B
P/E ratio
—
52W high
$53.65
52W low
$9.73
Volume
4,05,302
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Maze Therapeutics, Inc. share price today?
- Maze Therapeutics, Inc. (MAZE) last traded around $25.78 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MAZE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MAZE. Download the app for real-time alerts.
- How can I analyze Maze Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.